Acta obstetricia et gynecologica Scandinavica · 2008
Maternal use of thyroid hormones in pregnancy and neonatal outcome.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wikner Birgitta Norstedt, Sparre Lottie Skjöldebrand, Stiller Carl-Olav, Källén Bengt, Asker Charlotte
Аннотация
OBJECTIVE: To describe neonatal outcome including the presence of congenital malformations in infants born to women substituted with thyroid hormones, and the maternal characteristics of these women.
DESIGN: Register study based on prospectively collected data in relation to delivery.
SETTING: Swedish Health Registers.
POPULATION: All pregnant women (n=848,468) and all infants born (n=861,989) in Sweden from 1 July 1995 to 31 December 2004.
METHODS: Women who reported the use of thyroid hormones in early pregnancy or obtained a prescription for thyroid hormones later in pregnancy (n=9,866), as well as their infants (n=10,055) were identified from the Swedish Medical Birth Register. The reference population consisted of all women giving birth and their offspring during the same time interval.
MAIN OUTCOME MEASURES: Neonatal outcome, malformations and maternal characteristics. Data were analyzed with adjustments for identified confounders.
RESULTS: Women using thyroxine had an increased rate of pre-eclampsia, diabetes (pre-existing or gestational), cesarean sections and inductions of labour compared to women in the reference population. The risk for preterm birth was marginally increased (OR 1.13, 95% CI 1.03-1.25). Neonatal thyroid disease was found in eight infants (seven with thyreotoxicosis and one unspecified), the expected number was 0.2. No further anomalies in neonatal diagnoses were found. A small but statistically significant risk for congenital malformations (OR =1.14, 95% CI 1.05-1.26) was found.
CONCLUSION: Women on thyroid substitution during pregnancy had an increased risk for some pregnancy complications, but their infants were only slightly affected.
DESIGN: Register study based on prospectively collected data in relation to delivery.
SETTING: Swedish Health Registers.
POPULATION: All pregnant women (n=848,468) and all infants born (n=861,989) in Sweden from 1 July 1995 to 31 December 2004.
METHODS: Women who reported the use of thyroid hormones in early pregnancy or obtained a prescription for thyroid hormones later in pregnancy (n=9,866), as well as their infants (n=10,055) were identified from the Swedish Medical Birth Register. The reference population consisted of all women giving birth and their offspring during the same time interval.
MAIN OUTCOME MEASURES: Neonatal outcome, malformations and maternal characteristics. Data were analyzed with adjustments for identified confounders.
RESULTS: Women using thyroxine had an increased rate of pre-eclampsia, diabetes (pre-existing or gestational), cesarean sections and inductions of labour compared to women in the reference population. The risk for preterm birth was marginally increased (OR 1.13, 95% CI 1.03-1.25). Neonatal thyroid disease was found in eight infants (seven with thyreotoxicosis and one unspecified), the expected number was 0.2. No further anomalies in neonatal diagnoses were found. A small but statistically significant risk for congenital malformations (OR =1.14, 95% CI 1.05-1.26) was found.
CONCLUSION: Women on thyroid substitution during pregnancy had an increased risk for some pregnancy complications, but their infants were only slightly affected.